Who Actually Starts Semaglutide for Weight Loss? A Claims Data Analysis
Analysis of commercial insurance claims reveals which factors predict semaglutide initiation among adults with obesity but no diabetes.
Quick Facts
What This Study Found
Identified demographic and clinical factors associated with semaglutide initiation for obesity in commercially insured adults without diabetes.
Key Numbers
US adults aged 18+ with first obesity diagnosis June 2021-July 2022. Excluded prior AOM, GLP-1, bariatric surgery, or diabetes claims. Continuous enrollment required.
How They Did This
Retrospective observational cohort study using MarketScan Commercial Claims and Encounters Database.
Why This Research Matters
Understanding who accesses new obesity medications reveals potential disparities and informs efforts to ensure equitable treatment access.
The Bigger Picture
As anti-obesity medications become more mainstream, identifying access patterns helps address healthcare equity and coverage policy.
What This Study Doesn't Tell Us
Only commercially insured patients — excludes Medicare, Medicaid, and uninsured. Observational design cannot establish causation.
Questions This Raises
- ?Do access disparities differ across insurance types?
- ?How have initiation patterns changed since 2022 as awareness and supply have evolved?
Trust & Context
- Key Stat:
- JAMA Network Open Large claims database study identifying predictors of semaglutide initiation for obesity
- Evidence Grade:
- Large retrospective cohort from a national claims database — strong for identifying associations but limited by claims data completeness.
- Study Age:
- Published in 2025, covering the first year after semaglutide's obesity approval.
- Original Title:
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.
- Published In:
- JAMA network open, 8(1), e2455222 (2025)
- Authors:
- Podolsky, Meghan I, Raquib, Rafeya, Shafer, Paul R, Hempstead, Katherine, Ellis, Randall P, Stokes, Andrew C
- Database ID:
- RPEP-13068
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Who is most likely to start semaglutide for weight loss?
This study identified demographic and clinical factors associated with initiation among commercially insured adults with obesity but no diabetes.
Is semaglutide access equitable?
Studies like this help identify potential disparities in who starts treatment, informing efforts to improve equitable access.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13068APA
Podolsky, Meghan I; Raquib, Rafeya; Shafer, Paul R; Hempstead, Katherine; Ellis, Randall P; Stokes, Andrew C. (2025). Factors Associated With Semaglutide Initiation Among Adults With Obesity.. JAMA network open, 8(1), e2455222. https://doi.org/10.1001/jamanetworkopen.2024.55222
MLA
Podolsky, Meghan I, et al. "Factors Associated With Semaglutide Initiation Among Adults With Obesity.." JAMA network open, 2025. https://doi.org/10.1001/jamanetworkopen.2024.55222
RethinkPeptides
RethinkPeptides Research Database. "Factors Associated With Semaglutide Initiation Among Adults ..." RPEP-13068. Retrieved from https://rethinkpeptides.com/research/podolsky-2025-factors-associated-with-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.